ad
This Article
Right arrow Full Version
Services
Right arrow E-mail this link to a friend
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Section 1
Section 2
Section 3
Section 4
Section 5
Appendices
Right arrow Earn CME - What's This?
Related Collections
Right arrowRelated Article

The first 20% of the full text of this section appears below.

Section 2. Recommendations for Care of Children in Special Circumstances

Blood Safety: Reducing the Risk of Transfusion-Transmitted Infections

Improving Blood Safety

A number of strategies have been proposed or implemented to further decrease the risk of transmission of infectious agents through blood and blood products. Various safety strategies are as follows.

Elimination of Infectious Agents
Decreasing Exposure to Blood Products
Surveillance for Transfusion-Transmitted Infection
Organ and Tissue Transplantation

Top
 Next

ELIMINATION OF INFECTIOUS AGENTS

AGENT INACTIVATION Virtually all Plasma derivatives, including Immune Globulin Intravenous (IGIV) and clotting factors, are treated to eliminate infectious agents that may be present despite screening measures. Methods used for this include wet and dry heat and treatment with a solvent/detergent. Solvent/detergent-treated pooled Plasma for transfusion no longer is marketed in the United States, but methods of treating single-donor Plasma are under study. Solvent/detergent treatment dissolves the lipid envelope of HIV, HBV, and HCV but is not effective against non–lipid-enveloped viruses, such as HAV and parvovirus B19. Transmission of HIV through administration of IGIV never has been documented.

Because of the fragility of Red Blood Cells and Platelets, pathogen inactivation is more difficult. However, several methods have . . . [Go to Full Text]


Related Article

MedWatch—The FDA Safety Information and Adverse Event Reporting Program
Red Book 2009 2009: 817-818. [Extract] [Full Text]